Bernt Van Den Blink
Rotterdam, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): a randomised, double-blinded, multicentre, phase 2 study.
Journal: The European respiratory journal
Published: September 04, 2025
Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): A randomized, double-blinded, multicenter, Phase 2 study.
Journal: The European respiratory journal
Published: September 04, 2025
Prognostic biomarkers for idiopathic pulmonary fibrosis: findings from ISABELA clinical trials.
Journal: ERJ open research
Published: July 01, 2025
Design of RESOLVE Lung, a multinational Phase 2, randomized, placebo-controlled trial of the anti-GM-CSF monoclonal antibody namilumab in patients with chronic pulmonary sarcoidosis.
Journal: Contemporary clinical trials
Published: March 03, 2025
Development and validation of a predictive 6-min walk score in patients with idiopathic pulmonary fibrosis.
Journal: The European respiratory journal
Published: December 30, 2024
Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials.
Journal: JAMA
Published: May 09, 2023
ISABELA Studies: Plasma Exposure and Target Engagement Do Not Explain the Lack of Efficacy of Ziritaxestat in Patients with Idiopathic Pulmonary Fibrosis.
Journal: Clinical pharmacology and therapeutics
Published: April 05, 2023
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study.
Journal: The Lancet. Respiratory medicine
Published: February 28, 2019
Daily home spirometry to detect early steroid treatment effects in newly treated pulmonary sarcoidosis.
Journal: The European respiratory journal
Published: August 05, 2017
Last Updated: 09/26/2026